Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
06 juil. 2022 00h40 HE | HUTCHMED (China) Limited
SAN DIEGO and SHANGHAI and HONG KONG and SYDNEY, Australia, July 06, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM;...